We analysed antibodies specific for human p53 in sera from primary breast cancer patients using three different immunoassays 
genes, as well as evidence of more general phenomena such as DNA repair defects and genetic instability. The most frequent specific moleular change is mutation and allele loss occurring in the p53 tumour-suppressor gene. The clinical significn of p53 alterations has been extensively studied in breast cancer because of the increasing incidence of breast cancer, high mortality rate, long-lasting subclinical phase and unsatisfactory treatment in the advanced stages. DNA-based molcular analysis of p53 mutations and the detection of abnormal levels of p53 protein in tumour tissue are useful prognostic tests and could be meaningful therapeutic indicators (Thor et al., 1992) .
Interest in p53 as a prognostic markcer originated from the work of Crawford et al. (1982) , who reported that 9% of sera from breast cancer patients contain detectable auto antibodies to p53 protein. Subsequently there have been reports of B-cell responses to p53 protein in patients with diverse types of tumours (Caron de Fromentel et al., 1987; Angelopoulou and Diamandis, 1992; Davidoff et al., 1992; Hassapoglidou and Diamandi, 1992; Winter et al., 1992; Lubin et al., 1993; Schlichtholz et al., 1994 or in insect cells infected with a recombinant baculovirus. These p53 proteins were purified as described elswhere Hupp et al., 1992) .
Immunoprecipitation of the p53 protein from labelled cells (lysis buffer: 150mM sodium chlonde 50 mM Tris pH 8.0, 5 mM EDTA, 1% NP40, 1 mM PMSF) with 2 and 4 uld of the patients' sera and control MAbs was performed essentially as described previously (Gannon et al., 1990 Table I .
In the ELISA using recombinant wild-type p53 protein purified from a baculovirus expression system as a solid phase, 25 out of 100 sera (25%) were found to be p53 reactive in that they showed selective binding to the p53-coated plates as opposed to the BSA-coated plates. The titre of these sera in this assay was always very low (maximum 1:500 compared with a maximum of 1:10000 for specific polyclonal antibodies raised against p53 The p53 status of breast cancer patients has been assessed by various studies at the DNA and protein levels, and the data so far suggest that there is a correlation between high p53 levels and unfavourable disease prognosis (Thor et al., 1992; Alred et al., 1993; Vojtesek et al., 1993) . The possible immune self recognition of the aberrant p53 protein and formation of specific antibodies in patient sera could potentially provide a new approach in detecting p53 tumourrelated changes by means of a relatively simple serological assay. However, while the immunogenicity of p53 protein in xenogenic systems has been well established and can be documented by a number of monoclonal antibodies developed in various animal species immunised with p53 protein, the frequency of the production of autoantibodies to p53 in humans is still unclear.
We report on the failure to detect circulating p53 autoantibodies in a clinically meaningful number of mammary cancer patients using three different immunoassays. Out of 100 breast cancer patient sera collected from two areas with substantially different demographic characteristics (i.e. 80 sera from Europe and 20 sera from South America), circulating p53 autoantibodies were clearly noted in only one patient of European origin. This result is in apparent disagreement with the findings of other authors (Crawford et al., 1982; Caron de Fromentel et al., 1987; Angelopoulou and Diamandis, 1992; Davidoff et al., 1992; Winter et al., 1992; Lubin et al., 1993; Schlichtholz et al., 1994) , who found p53 serum antibodies in a much higher, though variable, proportion of breast cancer patients, ranging from 5% to 25% of positive cases. Undoubtedly, differences in the assay systems, the number of patients examined and genetic heterogeneity of the patients studied might account for these variations in results. Because of the limitations of individual assays and possible misinterpretation of results, we included additional negative controls, for example the use of lysates from cells not expressing p53 enabled us to exclude several falsepositive findings. Our ELISA showed that 25% of the sera, regardless of whether they originated from patients with 'p53-positive' or 'p53-negative' tumours, have antibodies which apparently recognise human p53 protein. Winter et al. (1992) , Lubin et al. (1993) and Schlichtholz et al. (1994) , seem to argue that the fraction of true positives in these breast cancers is so low that the determination of p53 antibody status is unlikely to be of major use in the detection of occult disease. An important factor that could control the level of genuine anti-p53 antibodies present in sera may be the stage of the disease, since our study has specifically focused on the arguably clinically more relevant stages. To confirm this hypothesis we plan to carry out further studies of late-stage patient sera.
